1Hirsh J,Guyatt G,Albers GW,et al.Executive summary:American college of chest physicians evidence-based clinical practice guidelines (8th Edition).2008,Chest,133:71S-109S.
2Turpie AG,Bauer KA,Eriksson BI,et al.Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery:a meta-analysis of 4 randomized double-blind studies.Arch Intern Med,2002,162:1833-1840.
3Eriksson BI,Lassen MR.Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery:a multicenter,randomized,placebo-controlled,double-blind study.Arch Intern Med,2003,163:1337-1342.
4Turpie A,Bauer K,Caprini J,et al.Fondaparinux combined with intermittent pneumatic compression vs.intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery:a randomized,double-blind comparison.J Thromb Haemost,2007,5:1854-1861.
5Buller HR,Davidson BL,Decousus H,et al.Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.N Engl J Med,2003,349:1695-1702.
6Sculpher MJ,Lozano-Ortega G,Sambrook J,et al.Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes; short-term cost and long-term cost-effectiveness using data from the fifth organization to assess strategies in acute ischemic syndromes investigators (OASIS-5) trial.Am Heart J,2009,157:845-852.
7Karthikeyan G,Mehta SR,Eikelboom JW.Fondaparinux in the treatment of acute coronary syndromes:evidence from OASIS 5 and 6.Expert Rev Cardiovasc Ther,2009,7:241-249.
8Joyner CD,Peters RJ,Afzal R,et al.Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation:outcomes and treatment effect across different levels of risk.Am Heart J,2009,157:502-508.
9Mehta SR,Boden WE,Eikelboom JW,et al.Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST-and non-ST-segment elevation acute coronary syndromes:an individual patient-level combined analysis of the fifth and sixth organization to assess strategies in ischemic syndromes (OASIS 5 and 6) randomized trials.Circulation,2008,118:2038-2046.
10Yusuf S,Mehta SR,Chrolavicius S,et al.Comparison of fondaparinux and enoxaparin in acute coronary syndromes.N Engl J Med,2006,354:1464-1476.
